

**Highlight of the session “Pharmacovigilance and Drug Risk Management” during the Forbidden City International Pharmacist Conference 2021**

The Forbidden City International Pharmacist Conference is a well-known conference in the Chinese clinical pharmacy field. It has been held in Beijing every year 13 times since 2009. Centered on the concept of “Collaborative Practice” based on national pharmaceutical policy, pharmaceutical management, and practical work experience of pharmacists, the annual conference invites many well-known experts, scholars, and government officials from abroad and China to carry out in-depth conversations and discussions. The conference aims to provide an international learning and communicating platform for pharmacists. Entitled “Reform and Innovation—Promoting the Development of Pharmaceutical Care”, this year's conference was hosted by the Zhongguancun Zhuoyi Institute of Scientific and Technological Innovation in Non-communicable Disease Prevention and Control and the Zhongguancun Healthcare Support and Technological Innovation Center.

Due to the Coronavirus pandemic, the conference was launched and broadcast online and was held between 3<sup>rd</sup> and 10<sup>th</sup> September 2021.

On 7<sup>th</sup> September 2021, presented by the International Society of Pharmacovigilance (ISoP) China Chapter and the Clinical Toxicology Committee of Chinese Society of Toxicology, the session “Pharmacovigilance and Drug Risk Management” was successfully held. It was organized and co-chaired by Professor Li Zhang, ISoP Board Member & ISoP China Chapter EC Member and Professor Haibo Song, chairman of the Clinical Toxicology Committee of Chinese Society of Toxicology. A total of 6 experts from China and abroad gave lectures to more than 6900 online participants. They were Professor Zhigang Zhao from Beijing Tiantan Hospital Affiliated to Capital Medical University, Professor Li Zhang from Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Dr. Andrew Bate, Vice President and head of Safety Innovation and Analytics at GlaxoSmithKline, Professor Wanjun Chen from E-DA hospital, Xiaole Zhang, President of PSM Beijing

Foundation and Professor Fang Liu from the Peking University Third Hospital. They respectively reported “The cross-sectional study on pharmacovigilance and ADR reports in Chinese hospitals”, “Pharmacovigilance for Traditional Chinese Medicinal Drugs: Current status and future perspective”, “Safety surveillance—current approaches and future horizons”, “The introduction of intelligent adverse drug reaction management mechanism and the drug safety of developers” and the construction of pharmacovigilance ecosystem based on “thrombin case” and “National baseline survey on perception, belief, and practice of pharmacovigilance”.

Professor Li Zhang, the chair of this session, delivered the remarks at the closing ceremony, with gratitude to all experts for sharing practical experience and research frontiers from different perspectives, including clinical, scientific research, and supervision, discussing the current hot topics in pharmacovigilance from abroad and China as well as the development trend of the industry. She emphasized that clinical pharmacists played an important role in pharmacovigilance activities. This successful session will further improve the level of clinical pharmaceutical care and scientific research, widen the scope of pharmacovigilance research and ensure the safety and effectiveness of drug use globally. ISoP has built an international platform for pharmacovigilance technology communication and knowledge sharing for industry insiders. ISoP China Chapter is willing to continually contribute to the improvement of pharmacovigilance technology in China through the development of pharmacovigilance academic activities.

(Yalu Wen, Tianyi Yang, Jiaoyue Li)